AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Guanine nucleotide-binding protein subunit beta-4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9HAV0

UPID:

GBB4_HUMAN

Alternative names:

Transducin beta chain 4

Alternative UPACC:

Q9HAV0; B3KMH5; D3DNR8

Background:

Guanine nucleotide-binding protein subunit beta-4, also known as Transducin beta chain 4, plays a pivotal role in transmembrane signaling systems. It functions as a modulator or transducer, facilitating the GTPase activity, GDP to GTP replacement, and G protein-effector interaction. This protein's involvement in cellular communication underscores its importance in maintaining physiological balance.

Therapeutic significance:

The protein is linked to Charcot-Marie-Tooth disease, dominant intermediate F, a peripheral nervous system disorder characterized by muscle atrophy and weakness. Understanding the role of Guanine nucleotide-binding protein subunit beta-4 in this condition could pave the way for innovative therapeutic strategies targeting the molecular mechanisms underlying the disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.